Recorded on 01/27/23

Drug pricing is an ongoing source of anxiety for biopharma investors. A critical debate in the marketplace is whether the Inflation Reduction Act will cut drug prices. This episode features Steve Scala, Cowen senior research analyst covering the pharmaceutical industry, and his teammate, Mike Nedelcovych, who joined Cowen about four years ago from Johns Hopkins Drug Discovery after co-founding a biotech startup. We discuss the results of Cowen’s 28th annual drug pricing survey, its historical context, what the survey says about the pricing outlook, biosimilar competition, gross-to-net discounts, and survey insights related to obesity drugs.

For Disclosures, click here bit.ly/3cPHkNW

https://go.td.com/PodcastDisclosure